Fed governors may dissent against Powell amid Trump pressure - WSJ’s Timiraos
Theravance Biopharma, Inc. (NASDAQ:TBPH), a $538.51 million market cap company with strong financial health indicators and a current ratio of 4.77, announced a settlement agreement with Eugia Pharma Specialities Ltd. regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The agreement, detailed in a recent SEC filing, was reached between Theravance’s subsidiaries and Mylan (NASDAQ:VTRS), its partner in the drug’s development, and Eugia.
The litigation stemmed from Eugia’s filing of an abbreviated new drug application (ANDA) to market a generic version of YUPELRI® before the expiration of Theravance and Mylan’s patents. The patents in question include several U.S. Patent Nos., such as 8,541,451 and 12,285,417, among others.
Under the terms of the settlement, Theravance and Mylan have granted Eugia a royalty-free, non-exclusive license to manufacture and market its generic version of YUPELRI® in the United States starting April 23, 2039. This agreement is subject to customary exceptions and regulatory review by the U.S. Department of Justice and the Federal Trade Commission. The company’s stock has shown significant momentum, posting a 17.58% return over the past week, with revenue growth of 6.11% in the last twelve months.
The settlement resolves the dispute with Eugia but does not affect ongoing litigation with other ANDA filers, including Cipla (NSE:CIPL) Limited and Mankind Pharma Ltd. The settlement is part of Theravance’s strategy to protect its intellectual property while allowing for eventual generic competition.
The information is based on a press release statement filed with the SEC. For detailed financial analysis and exclusive insights about Theravance Biopharma, including Fair Value estimates and comprehensive financial health scores, visit InvestingPro.
In other recent news, Theravance Biopharma reported mixed financial results for the first quarter of 2025. The company posted an earnings per share (EPS) of -$0.27, falling short of the expected -$0.22, while revenue slightly exceeded forecasts, reaching $15.4 million. Despite the EPS miss, Theravance Biopharma saw a 6% year-over-year revenue increase, supported by strong sales growth in key product lines, YUPELRI and TRELEGY. The company ended the quarter with $131 million in cash and no debt, maintaining a strong financial position. In a strategic move, Theravance Biopharma sold rights to future royalties on Trelegy net sales to GlaxoSmithKline (NYSE:GSK) for a $225 million cash payment, while retaining the potential to earn up to $150 million in tiered commercial milestones. BTIG analysts maintained a Buy rating on the company’s stock, citing attainable sales thresholds for future milestones. The ongoing CYPRESS trial is progressing, with enrollment expected to conclude in late summer 2025, and data disclosure anticipated in the first half of 2026. Theravance Biopharma continues to anticipate improved cash burn and a decline in clinical trial costs in the second half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.